Drug intelligence / Profile preview

ART-44

Development stage: Phase 3
Lead developer: NEGMA
Modality: Small Molecules

Overview

ART-44 is an investigational drug initially developed by Laboratoires Negma SAS. It has been studied primarily for the treatment of osteoarthritis of the knee and other skin and musculoskeletal diseases. The most notable clinical trial was a Phase 3 randomized, double-blind study comparing the digestive tolerability (especially diarrhea) of ART-44 versus another formulation, ART®50, in patients with knee osteoarthritis. The precise mechanism of action, molecular target(s), and chemical class for ART-44 have not been publicly disclosed as of March 2025. Its global highest R&D status is listed as "Pending," indicating it has not yet received regulatory approval or completed late-stage development[7].

Other names: ART 44ART44ART-44

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on ART-44.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART-44.

Explore the full profile